CD274 and neoplasm: Survival curves by smoking status, line of TKI treatment, or PD-L1 expression levels did not reveal a PFS or OS benefit for chemotherapy plus ICI, except for patients whose tumor had PD-L1 expression scores between one and 49, who had a favorable OS prolongation with the addition of ICI.